Arrowpoint Investment Partners Singapore Pte. Ltd. Takes Position in Genmab A/S Sponsored ADR $GMAB

Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 43,228 shares of the company’s stock, valued at approximately $1,331,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Osaic Holdings Inc. grew its stake in shares of Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after buying an additional 440 shares during the last quarter. NewEdge Advisors LLC lifted its stake in shares of Genmab A/S by 1,229.0% in the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after acquiring an additional 1,143 shares during the last quarter. Brown Brothers Harriman & Co. boosted its holdings in shares of Genmab A/S by 143.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after acquiring an additional 780 shares in the last quarter. Founders Capital Management grew its position in Genmab A/S by 40.0% during the 4th quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after acquiring an additional 400 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in Genmab A/S by 124.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock worth $44,000 after acquiring an additional 1,174 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Morgan Stanley assumed coverage on Genmab A/S in a research report on Monday, February 16th. They issued an “equal weight” rating and a $34.00 target price for the company. Wolfe Research started coverage on Genmab A/S in a research note on Friday, March 27th. They issued an “outperform” rating and a $32.00 price objective for the company. Jefferies Financial Group assumed coverage on shares of Genmab A/S in a report on Tuesday, February 17th. They issued a “buy” rating and a $41.50 price objective for the company. Wells Fargo & Company started coverage on shares of Genmab A/S in a research report on Monday, March 2nd. They issued an “overweight” rating and a $40.00 price target for the company. Finally, Guggenheim dropped their price target on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, February 23rd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $39.36.

Genmab A/S Price Performance

Shares of NASDAQ GMAB opened at $27.50 on Friday. Genmab A/S Sponsored ADR has a twelve month low of $17.24 and a twelve month high of $35.43. The firm has a fifty day simple moving average of $28.83 and a 200 day simple moving average of $30.42. The company has a market capitalization of $17.67 billion, a PE ratio of 17.74, a P/E/G ratio of 1.24 and a beta of 0.97. The company has a quick ratio of 2.01, a current ratio of 2.02 and a debt-to-equity ratio of 0.86.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. On average, sell-side analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.